Published online
doi:10.1084/jem.20082826
The Journal of Experimental Medicine, Vol. 206, No. 4, 953-966
The Rockefeller University Press, 0022-1007 $30.00
© Bougdour et al.
Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites
Alexandre Bougdour1,
Danièle Maubon1,2,
Patricia Baldacci6,
Philippe Ortet3,
Olivier Bastien4,
Anthony Bouillon5,
Jean-Christophe Barale5,
Hervé Pelloux1,2,
Robert Ménard6, and
Mohamed-Ali Hakimi1
1 UMR5163, Laboratoire Adaptation et Pathogénie des Micro-organismes, Centre National de la Recherche Scientifique (CNRS), Université Joseph Fourier Grenoble 1, BP 170, 38042 Grenoble, Cedex 09, France
2 Parasitologie–Mycologie, Département des Agents Infectieux, Centre Hospitalier Universitaire, BP 217, 38043 Grenoble, Cedex 09, France
3 Commissariat à l'Energie Atomique (CEA), Institut de Biologie Environnementale et Biotechnologie, CNRS, Université Aix-Marseille II, CEA Cadarache, 13108 Saint-Paul-lez-Durance, France
4 UMR 5168, CNRS, Institut Scientifique de Recherche Agronomique, Université Joseph Fourier, CEA, 38054 Grenoble, Cedex 09, France
5 Unité d'Immunologie Moléculaire des Parasites, Département de Parasitologie et de Mycologie, Unité de Recherche Associée, CNRS 2581, Institut Pasteur, 75724 Paris, Cedex 15, France
6 Unité de Biologie et Génétique du Paludisme, Institut Pasteur, 75724 Paris, Cedex 15, France
CORRESPONDENCE Mohamed-Ali Hakimi: Mohamed-ali.hakimi{at}ujf-grenoble.fr
Plasmodium and Toxoplasma are parasites of major medical importance that belong to the Apicomplexa phylum of protozoa. These parasites transform into various stages during their life cycle and express a specific set of proteins at each stage. Although little is yet known of how gene expression is controlled in Apicomplexa, histone modifications, particularly acetylation, are emerging as key regulators of parasite differentiation and stage conversion. We investigated the anti-Apicomplexa effect of FR235222, a histone deacetylase inhibitor (HDACi). We show that FR235222 is active against a variety of Apicomplexa genera, including Plasmodium and Toxoplasma, and is more potent than other HDACi's such as trichostatin A and the clinically relevant compound pyrimethamine. We identify T. gondii HDAC3 (TgHDAC3) as the target of FR235222 in Toxoplasma tachyzoites and demonstrate the crucial role of the conserved and Apicomplexa HDAC-specific residue TgHDAC3 T99 in the inhibitory activity of the drug. We also show that FR235222 induces differentiation of the tachyzoite (replicative) into the bradyzoite (nonreplicative) stage. Additionally, via its anti-TgHDAC3 activity, FR235222 influences the expression of
370 genes, a third of which are stage-specifically expressed. These results identify FR235222 as a potent HDACi of Apicomplexa, and establish HDAC3 as a central regulator of gene expression and stage conversion in Toxoplasma and, likely, other Apicomplexa.
Abbreviations used: AcH4, acetylated histone H4; ChIP, chromatin immunoprecipitation; EST, expressed sequence tag; HDAC, histone deacetylase; HDACi, HDAC inhibitor; HDLP, HDAC-like protein; HFF, human foreskin fibroblast; IFA, immunofluorescence analysis; IMC1, inner membrane complex protein 1; NEU, N-nitroso-N-ethylurea; SRS, surface antigen glycoprotein–related sequence; TgHDAC3, T. gondii HDAC3; TSA, trichostatin A; TSS, transcription start site.
© 2009 Bougdour et al.
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

CiteULike
Complore
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter What's this?